NCT01682694

Glucosamine and Chondroitin Effects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Fred Hutchinson Cancer Center · Academic / Other
• Sex: All
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.

Detailed description

Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.

Conditions

• Inflammation

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Glucosamine and Chondroitin	Glucosamine (1500 mg) and Chondroitin (1200 mg)
DIETARY_SUPPLEMENT	placebo

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2012-09-11
• Last updated: 2014-05-28

Locations

1 site across 1 country: United States